Withdrawal and Dose Reduction of Pioglitazone in Patients with Type 2 Diabetes: A Chart-Based Analysis

Withdrawal and Dose Reduction of Pioglitazone in Patients with Type 2 Diabetes: A Chart-Based Analysis - Withdrawal and Dose Reduction of Pioglitazone

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018104

Enrollment

Registered

2015-06-26

Start date

2014-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes Patients who underwent dose reduction and withdrawal of pioglitazone

Exclusion criteria

Exclusion criteria: Type 1 diabetes Secondary diabetes

Design outcomes

Primary

Measure	Time frame
The change of body weight, plasma glucose, HbA1c, HDL, LDL, TG, AST, ALT after the dose reduction and withdrawal of pioglitazone	—

Countries

Japan

Contacts

Public ContactHisayuki Katsuyama

National Center for Global Health and Medicine Kohnodai Hospital Department of Internal Medicine

katsuyama-hs@umin.org+81-47-272-0034

Outcome results